OGN
Organon & Co.
NYSE · USHealthcareDrug Manufacturers - General
$13.49-0.22%
Price as of Jul 20, 2026
OGN financials
Organon & Co. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $6.2B | $6.4B | $6.3B | $6.2B |
| Cost of revenue | $2.9B | $2.7B | $2.5B | $2.3B |
| Gross profit | $3.4B | $3.7B | $3.7B | $3.9B |
| Operating expenses | $2.1B | $2.2B | $2.4B | $2.2B |
| Operating income | $1.3B | $1.5B | $1.3B | $1.7B |
| Net income | $187.0M | $864.0M | $1.0B | $917.0M |
| EBITDA | $1.3B | $1.6B | $1.4B | $1.8B |
| Basic EPS | $0.72 | $3.36 | $4.01 | $3.61 |
| Diluted EPS | $0.72 | $3.33 | $3.99 | $3.59 |
| Balance sheet | ||||
| Cash & equivalents | $574.0M | $675.0M | $693.0M | $706.0M |
| Total assets | $12.9B | $13.1B | $12.1B | $11.0B |
| Total liabilities | $12.1B | $12.6B | $12.1B | $11.8B |
| Stockholders’ equity | $752.0M | $472.0M | -$70.0M | -$892.0M |
| Total debt | $8.8B | $9.0B | $8.9B | $9.1B |
| Net debt | $8.2B | $8.4B | $8.2B | $8.4B |
| Cash flow | ||||
| Operating cash flow | $700.0M | $939.0M | $799.0M | $858.0M |
| Capital expenditure | -$162.0M | -$351.0M | -$261.0M | -$427.0M |
| Free cash flow | $538.0M | $588.0M | $538.0M | $431.0M |
| Dividends paid | -$88.0M | -$297.0M | -$294.0M | -$290.0M |
| Share repurchases | $0.00 | -$22.0M | -$17.0M | $0.00 |